Heart Rate Linked to Fatigue in Liver Cancer
A small exploratory study found heart rate variability differences among liver cancer patients reporting severe fatigue.
Updated on Nov. 4, 2026 in Cancer
Researchers studying 66 patients receiving interventional therapy for hepatocellular carcinoma found that half met the threshold for severe fatigue. Those with severe fatigue had a higher mean heart rate, and the association held after adjusting for age.
Why it matters
Fatigue is a common and difficult-to-measure symptom for people with cancer, and a physiological marker could complement questionnaire-based assessments. The findings are preliminary, however, and cannot establish cause and effect.
The exploratory cross-sectional design of 66 patients yielded an age-adjusted area under the ROC curve of 0.785, compared with 0.5 for chance. Whether these associations replicate in larger samples remains unknown.
The details
Participants completed the Pittsburgh Sleep Quality Index and the Fatigue Scale-14 questionnaires, and researchers recorded a five-minute resting electrocardiogram to assess heart rate variability. Eight heart rate variability parameters differed significantly between fatigue groups after multiple-comparison correction.
Health Landscape
Fatigue is routinely assessed with questionnaires such as the Fatigue Scale-14, which rely on self-report. This exploratory work asks whether objective autonomic measures, such as heart rate variability, could add to those tools in liver cancer care.
Patients experiencing persistent tiredness during cancer treatment may eventually benefit from objective measures that help clinicians track fatigue alongside self-reported symptoms. For now, the findings do not change how fatigue is managed.
The takeaway
Fatigue in cancer patients is real and measurable, but heart rate patterns alone are not yet a diagnostic tool. Patients experiencing severe tiredness should continue to discuss symptoms with their oncology team.
Further reading
For more on how cancer treatment affects patients over time, see the Cancer section.
Source note: This article includes information reported by European Medical Journal.
